ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 102 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2016. The put-call ratio across all filers is 0.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $80,000 | +166.7% | 1,348 | +68.1% | 0.00% | – |
| Q3 2019 | $30,000 | -21.1% | 802 | -3.0% | 0.00% | – |
| Q2 2019 | $38,000 | +15.2% | 827 | 0.0% | 0.00% | – |
| Q1 2019 | $33,000 | -31.2% | 827 | -21.0% | 0.00% | – |
| Q4 2018 | $48,000 | +336.4% | 1,047 | +349.4% | 0.00% | – |
| Q3 2018 | $11,000 | -85.1% | 233 | -77.0% | 0.00% | -100.0% |
| Q2 2018 | $74,000 | 0.0% | 1,015 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $74,000 | -26.7% | 1,015 | -33.4% | 0.00% | 0.0% |
| Q4 2017 | $101,000 | +27.8% | 1,524 | -2.6% | 0.00% | 0.0% |
| Q3 2017 | $79,000 | +61.2% | 1,564 | +49.0% | 0.00% | 0.0% |
| Q2 2017 | $49,000 | +58.1% | 1,050 | +18.5% | 0.00% | – |
| Q1 2017 | $31,000 | +181.8% | 886 | -1.6% | 0.00% | – |
| Q4 2016 | $11,000 | -8.3% | 900 | 0.0% | 0.00% | – |
| Q3 2016 | $12,000 | +33.3% | 900 | 0.0% | 0.00% | – |
| Q2 2016 | $9,000 | -40.0% | 900 | 0.0% | 0.00% | – |
| Q1 2016 | $15,000 | -25.0% | 900 | 0.0% | 0.00% | – |
| Q4 2015 | $20,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $59,618,000 | 21.09% |
| Bellevue Group AG | 4,519,164 | $95,580,000 | 0.93% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $36,234,000 | 0.84% |
| Rhenman & Partners Asset Management AB | 572,267 | $12,103,000 | 0.82% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 64,434 | $1,363,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $10,575,000 | 0.37% |
| EMC Capital Management | 27,566 | $583,000 | 0.33% |
| WASATCH ADVISORS LP | 3,766,935 | $79,671,000 | 0.32% |
| Avidity Partners Management LP | 400,000 | $8,460,000 | 0.23% |
| Cinctive Capital Management LP | 186,170 | $3,937,000 | 0.18% |